focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 112.20
Bid: 111.20
Ask: 112.60
Change: 0.00 (0.00%)
Spread: 1.40 (1.259%)
Open: 112.80
High: 112.80
Low: 111.80
Prev. Close: 112.20
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

Mon, 27th Nov 2023 19:03

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Saietta Group PLC - Towcester, England-based designer, engineer and manufacturer of 'eDrive' solutions for electric vehicles - Proposes placing and subscription of new shares to raise a minimum GBP5.2 million, pricing each share at 17 pence each. This is alongside a broker option to Canaccord Genuity Ltd for an additional GBP1.0 million. The fundraising is being conducted in two tranches: around GBP1.7 million raised via the firm fundraising and a minimum of GBP4.7 million via a conditional fundraising. The fundraising is expected to satisfy the company's working capital requirements through to the end of March 2024, by which time the company is expecting to have announced a number of major commercial developments.

----------

Syncona Ltd - London-based investor in healthcare companies - Notes that its portfolio company Autolus Therapeutics PLC submits biologics licence application to US Food & Drug Administration for obecabtagene autoleucel for patients with relapsed/refractory adult B-Cell acute lymphoblastic leukaemia. Says submission is based on data from the Felix study. Says Autolus has also made "significant" progress in preparing its manufacturing footprint for the planned commercial launch of obe-cel, with its new 70,000 square foot commercial manufacturing facility, The Nucleus, which has an initial designed capacity of 2,000 batches per year. Pending approval from the Food & Drug Administration for the biologics licence application submission, the company expects to initiate its commercial launch of obe-cel in the US in 2024. It also expects to file a marketing authorisation application for obe-cel with the European Medicines Agency in the first half of 2024.

----------

Molten Ventures PLC - London-based venture capital firm - Completes GBP55.0 million placing and subscription of 20.4 million new shares priced at 270p each, representing around 13% of all shares. The retail offer remains open and is expected to close on Tuesday at 1500 GMT.

----------

Quadrise PLC - London-based residual oil technology company - Says all resolutions pass at annual general meeting, but notes resolution 3 only passed with 68% of shareholders voting in favour. Resolution 3 relates to re-appointing Non-Executive Director Dilip Shah, who is to retire by rotation. The company says on this: "The board is committed to continuing our engagement with shareholders to understand the views of those who voted against resolution 3 and will consult with them over the next few months to listen carefully to feedback and determine any next steps."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
31 Mar 2021 09:18

Syncona says Achilles stake leaps to GBP145 million value after IPO

Syncona says Achilles stake leaps to GBP145 million value after IPO

Read more
31 Mar 2021 07:41

Achilles Therapeutics prices IPO at $175m as Syncona keeps 27% stake

(Sharecast News) - Syncona portfolio biopharma company Achilles Therapeutics said its US initial public offering (IPO) will raise $175.5m (£127.8mln).

Read more
30 Mar 2021 16:01

DIRECTOR DEALINGS: Gym Group directors sell GBP1.8 million in shares

DIRECTOR DEALINGS: Gym Group directors sell GBP1.8 million in shares

Read more
26 Mar 2021 09:20

Syncona invests USD42 million into Gyroscope to have 54% stake

Syncona invests USD42 million into Gyroscope to have 54% stake

Read more
26 Mar 2021 07:59

Syncona invests £31m in Gyroscope

(Sharecast News) - Syncona has invested $42.3m (£31m) in Gyroscope Therapeutics as part of a $148m financing by the retinal gene therapy company.

Read more
25 Mar 2021 12:23

Syncona portfolio firm Achilles Therapeutics prices US share offering

Syncona portfolio firm Achilles Therapeutics prices US share offering

Read more
4 Mar 2021 12:46

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

Read more
2 Mar 2021 13:45

IN BRIEF: Syncona investee Achilles Therapeutics files for US IPO

IN BRIEF: Syncona investee Achilles Therapeutics files for US IPO

Read more
12 Feb 2021 16:24

IN BRIEF: Syncona's Gyroscope Reports Positive Results From GT005 Test

IN BRIEF: Syncona's Gyroscope Reports Positive Results From GT005 Test

Read more
11 Feb 2021 10:05

Syncona Net Asset Value Dips In Third Quarter, Invests More In Quell

Syncona Net Asset Value Dips In Third Quarter, Invests More In Quell

Read more
11 Feb 2021 07:56

Syncona makes decent progress in December quarter

(Sharecast News) - Healthcare investment company Syncona updated the market on its latest quarter on Thursday, reporting clinical, financial and operational progress across its portfolio in the three months ended 31 December.

Read more
10 Feb 2021 09:41

Syncona Investee Autolus Nets USD100 Million From ADS Offer

Syncona Investee Autolus Nets USD100 Million From ADS Offer

Read more
10 Feb 2021 09:31

Syncona upbeat on Autolus US public offering pricing

(Sharecast News) - Healthcare investor Syncona said on Wednesday that its portfolio company Autolus Therapeutics has priced its underwritten public offering in the United States at $7.00 per American depositary share (ADS).

Read more
8 Feb 2021 13:09

Syncona Investee Freeline Modifies Hemophilia Plan After FDA Feedback

Syncona Investee Freeline Modifies Hemophilia Plan After FDA Feedback

Read more
5 Feb 2021 08:20

Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO

Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.